Merge Healthcare Incorporated announced that OnQ Research Pty Ltd. has selected Merge's eClinical OS(TM) solution for electronic data capture (EDC) to expand their in-house data management service offering. Merge eClinical OS offers a single, easy-to-use interface for all data capture, processing and reporting functions needed to manage a trial. Clinical trial capabilities can be mixed and matched to build a solid foundation for each trial environment, and clients pay for only the functionality they need, when they need it. Plus, it delivers built-in study templates, libraries and reports to help users create studies quickly and manage them effectively without technical assistance. The latest advancements include the addition of a mobile alerts and reporting application, which allows users to review study data directly from any mobile web-enabled device. The mobile application is anticipated to be released later this month.

Merge Healthcare Incorporated provided earnings guidance for the third quarter and full year of 2013. The company continue to expect adjusted EBITDA of 22% to 24% for 2013. While the company expects $5 million of tax expense during 2013, of which only $1 million is cash taxes, $3 million of that expense was recorded in the quarter. The company expects total interest expense and related expenses of approximately $4 million for the third quarter of 2013, on a quarterly basis going forward. While none of these charges will impact adjusted EBITDA in the second quarter of 2013, the positive news is that starting in the third quarter, the company expects this transaction to add almost $0.04 of GAAP EPS on a quarterly basis. The end result is an expectation for the company to deliver both net income and EPS on a GAAP basis for the third quarter.

Merge Healthcare Incorporated announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total net sales of $63.634 million against $60.978 million a year ago. Operating income was $5.282 million against $5.673 million a year ago. Loss before income taxes was $3.478 million against $2.258 million a year ago. Net loss available to common shareholders was $6.475 million or $0.07 per basic and diluted share against $1.842 million or $0.02 per basic and diluted share a year ago. Net cash provided by operating activities was $8.687 million against $2.171 million a year ago. Purchases of property, equipment and leasehold improvements were $0.393 million against $1.743 million a year ago. Adjusted EBITDA was $12.502 million or $0.13 per diluted share against $12.495 million or $0.13 per diluted share a year ago. Adjusted net loss was $0.519 million or $0.01 per diluted share against adjusted net income of $2.890 million or $0.03 per diluted share a year ago. On pro-forma basis, net loss available to common shareholders was $6.166 million against $1.397 million a year ago. Pro forma net sales were $64.0 million against $61.6 million a year ago.